Oral vs IV Paclitaxel for HER2 Negative Breast Cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial compares an oral chemo pill (paclitaxel plus encequidar) to the standard IV paclitaxel for people with HER2 negative breast cancer that has spread. It aims to see if the oral option works as well or better and may be more convenient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2 negative breast cancer that has spread to other parts of the body.
- Your doctor has recommended treatment with IV paclitaxel alone.
- You have at least one tumor that can be measured on a CT scan.
- You are 18 years or older.
- Your blood counts, liver, and kidney function are within certain limits.
- You have not had strong side effects from prior cancer treatments (except hair loss).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how eating food affects how your body absorbs an oral (by-mouth) form of paclitaxel, a common cancer drug, when combined with a new medication called encequidar. The goal is to understand the best way to take this drug combination to treat advanced cancers like breast, lung, gastric, or ovarian cancer.
This trial tests a combination of low-dose oral paclitaxel (a chemotherapy pill taken regularly) plus immunotherapy to treat advanced breast cancer that doesn't have high levels of HER2 protein. The goal is to slow or shrink tumors while managing side effects better than traditional high-dose chemotherapy.
This trial tests if taking oral chemotherapy pills with trastuzumab (Herceptin) works as well as IV chemo (paclitaxel) with Herceptin after surgery for HER2-positive, lymph node-negative early breast cancer. It aims to find a more convenient treatment option.
This trial tests an oral form of paclitaxel combined with standard HER2 therapy given before surgery for HER2-positive breast cancer. It aims to find the best dose and see how well it works.
This trial tests a combination of two drugs, entinostat and a pill form of paclitaxel, for people with a type of advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if you have already tried several treatments, including hormone therapy with a CDK4/6 inhibitor and a chemotherapy with paclitaxel.
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.